Cargando…
High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure
Increased fibroblast growth factor 23 (FGF23) levels are an independent predictor for adverse cardiac events suggesting a role as a link that drives cardiomyopathic changes in cardiorenal syndrome. The search for the underlying mechanism driving this interaction has led to the hypothesis that FGF23...
Autores principales: | Moench, Ian, Aravindhan, Karpagam, Kuziw, Joanne, Schnackenberg, Christine G, Willette, Robert N, Toomey, John R, Gatto, Gregory J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275024/ https://www.ncbi.nlm.nih.gov/pubmed/34268460 http://dx.doi.org/10.1210/jendso/bvab066 |
Ejemplares similares
-
Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling
por: Czaya, Brian, et al.
Publicado: (2022) -
Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)(2)D and normal FGF7 concentrations characterize patients with CKD
por: Kritmetapak, Kittrawee, et al.
Publicado: (2021) -
A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
por: Wang, Joseph, et al.
Publicado: (2017) -
A Cross‐Sectional Cohort Study of the Effects of FGF23 Deficiency and Hyperphosphatemia on Dental Structures in Hyperphosphatemic Familial Tumoral Calcinosis
por: Lee, Alisa E, et al.
Publicado: (2021) -
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)